UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 13, 2007
The Medicines Company
(Exact Name of Registrant as Specified in Charter)
Delaware | | 000-31191 | | 04-3324394 |
(State or Other Jurisdiction | | (Commission | | (IRS Employer |
of Incorporation) | | File Number) | | Identification No.) |
8 Campus Drive | | |
Parsippany, New Jersey | | 07054 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (973) 656-1616
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 13, 2007, the Compensation Committee of the Board of Directors of The Medicines Company established the following 2007 base salaries for the Company’s executive officers, effective as of January 1, 2007, and awarded the following annual cash bonus payments to the Company’s executive officers for 2006.
| | 2007 Annual Base Salary | | 2006 Annual Cash Bonus
Payments | |
Clive A. Meanwell
Chief Executive Officer | | $ | 566,000 | | $ | 387,000 | |
John P. Kelley
President and Chief
Operating Officer | | $ | 450,000 | | $ | 250,000 | |
Glenn P. Sblendorio
Executive Vice President
and Chief Financial Officer | | $ | 375,000 | | $ | 165,000 | |
Catharine Newberry
Senior Vice President and
Chief Human Strategy Officer | | $ | 285,000 | | $ | 109,000 | |
Paul M. Antinori
Senior Vice President and
General Counsel | | $ | 315,000 | | $ | 139,200 | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | THE MEDICINES COMPANY |
| | | | |
| | | | |
Date: February 16, 2007 | | By: | | /s/ Paul M. Antinori |
| | | | Paul M. Antinori |
| | | | Senior Vice President and General Counsel |
3
